Lung Cancer

immuno therapy for lung cancer :: Article Creator Roche Immunotherapy Fails In Lung Cancer Study, Raising Questions About Drug's Target LONDON — An experimental cancer treatment from Roche failed to improve survival in a major lung cancer study, the company said Tuesday, a result that will further stoke doubts about the drug's target. In a short statement, Roche said that a combination of the drug, called tiragolumab, with its existing medicine Tecentriq did not outperform Tecentriq alone on the study's primary endpoint of overall survival. The Phase 3 study, known as SKYSCRAPER-01, included more than 500 patients with a form of advanced non-small cell lung cancer.  Tiragolumab was designed to target a protein called TIGIT, which in recent years was seen as the next blockbuster opportunity in cancer immunotherapy. Roche and other biopharma companies poured resources into standing up anti-TIGIT programs, thinking they could augment ...

leukemia treatment :: Article Creator Chromosomal Chaos Spurs Leukemia Treatment Breakthrough German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) Chromosomal instability plays a crucial role in the progression of cancer: it shapes the properties of tumor cells and drives the development of therapy resistance. Scientists from the German Cancer Research Center (DKFZ), the Heidelberg Stem Cell Institute HI-STEM* and the European Molecular Biology Laboratory (EMBL) used state-of-the-art single-cell analysis methods to analyze the cellular heterogeneity of a specific form of acute myeloid leukemia. Their data show how genetic and non-genetic factors determine the functional heterogeneity of blood cancer cells and reveal new therapeutic targets. In particular, under the selection pressure of cancer therapies, tumor cells undergo a veritable evolution to adapt to the changing conditions – and often escape the effects of therapy a...

squamous cell carcinoma stage 3 prognosis :: Article Creator Gum Cancer: Symptoms, Treatment, And More Gum cancer is a rare type of cancer that occurs in your mouth. Early diagnosis is important to treat this cancer, and it may be curable with a combination of surgery and other treatments. Gum cancer (gingival squamous cell carcinoma) is a rare type of cancer of the oral cavity. Oral cancers can affect areas throughout your mouth as well as the back of your throat. Gum cancers develop within the tissues of your gums, rather than the lips, inner cheeks, or other parts of your mouth. As a group, oral cancers make up about 3% of new cancer diagnoses each year. The majority of all gum cancers are squamous cell carcinomas and are considered rare. The challenging part about gum cancer is that its early symptoms may mimic other diseases of your gums, including gingivitis. However, like other oral cancers, gum cancer is aggressiv...

single station n2 lung cancer :: Article Creator

small cell carcinoma not in lungs :: Article Creator Why Is Small Cell Lung Cancer So Difficult To Treat? Small cell lung cancer (SCLC) is rarer than non-small cell lung cancer (NSCLC) but tends to be more difficult to treat. SCLC can be more resistant and aggressive than other cancers, which can increase the risk of relapses. Survival rates for many types of cancer have improved drastically over the last several decades. Despite this, SCLC survival rates have remained less favorable. From 2000 to 2016, the 5-year relative survival rate in the United States only improved from 6.0% to 8.7%. Most cases of SCLC have already spread to distant body parts when they're diagnosed. This is because SCLC is an aggressive cancer. Even though many people respond to initial treatment, the majority experience relapse. Researchers are still investigating why SCLC tends to be more resistant to treatment than most other cancers. ...

adjuvant nsclc :: Article Creator Adjuvant Durvalumab Does Not Improve Survival In Completely Resected NSCLC After complete resection of early-stage non-small cell lung cancer (NSCLC) and optimal chemotherapy, adjuvant durvalumab did not improve disease-free survival versus placebo in the international, double-blind, phase 3 BR.31 trial. Adjuvant chemotherapy improves 5 year survival in completely resected stage I-IIB NSCLC; however, approximately 60% of patients still relapse and die of disease1. Adjuvant immunotherapy with atezolizumab recently demonstrated improvement in disease-free survival (DFS) with limited benefit on overall survival2. The PD-L1 inhibitor durvalumab has proven efficacy as a peri-operative regimen in resectable NSCLC3. The Canadian Cancer Trials Group (CCTG) BR.31 trial (NCT02273375), conducted in 269 centers across 19 countries, aimed to evaluate the benefit of adjuvant durvalumab in early-stage, completely resected NSCL...

lung cancer :: Article Creator Never Smoked, Still Diagnosed: A Stage 4 Lung Cancer Journey WILMINGTON, NC (WWAY) — Meet Ruth McClellan. Diagnosed with stage 4 lung cancer in July 2020, Ruth's diagnosis came after a routine checkup and an unexpected cough. Having suffered from bronchitis her entire life, she didn't think much of the persistent cough until it wouldn't go away. "I had a chest x-ray, which showed a spot in my left lobe," Ruth recalls. "Then, I had a CAT scan, which showed a mass. A PET scan showed that I had cancer in my lung and in my skeletal system." Ruth's diagnosis was devastating, but it was only the beginning of her fight. In 2021, she had a brain lesion radiated, and she continues to monitor a spot where necrotic tissue is appearing, watching closely to ensure it doesn't reoccur. When most people hear "lung cancer," they often assume it's due to a heavy smoking...